FDA Fast Tracks Autologous Treg Therapy ABA-101 for Progressive Multiple Sclerosis

Published Date: 01 Sep 2024

ABA-101 has shown promising safety and anti-inflammatory effects in animal models, and Abata Therapeutics plans to initiate a Phase 1 study in 2024 to evaluate its potential for treating progressive multiple sclerosis.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Teenagers Frequently Use Delta-8 THC; New Drug-Coated Balloon Treats Blocked Stents.

2.

Even a few mutated cells can significantly impact how blood cancers develop, study finds

3.

GLP-1 RAs May Lower Hysterectomy Risk in Endometrial Cancer

4.

Advanced Solid Tumors May Benefit from Investigative Immunotherapy Combo.

5.

In Acute Leukemia With Heavily Pretreated Patients, Menin Inhibitor Yields 63 Percent ORR.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot